Case-Based Learning: Acute Liver Injury With Normal Initial Imaging

Abstract

Acute liver injury (ALI) is a complex clinical entity with a broad differential, often presenting diagnostic challenges, especially when initial imaging appears normal. This review explores the mechanisms, epidemiology, risk factors, and clinical presentation of ALI in such scenarios, integrating recent research and guideline-based recommendations. Through a case-based lens, we discuss the importance of high clinical suspicion, laboratory evaluation, and timely management. Emphasis is placed on emerging therapies and practical approaches for clinicians when imaging is inconclusive. The article aims to provide healthcare professionals with a structured, evidence-based framework for recognizing and managing ALI even when initial imaging does not reveal hepatic abnormalities.

Introduction

Acute liver injury denotes a rapid deterioration of hepatic function, typically manifesting as elevated aminotransferases, possible jaundice, and coagulopathy, in individuals with previously normal liver function. While imaging modalities such as ultrasonography and computed tomography are pivotal in the initial evaluation, a subset of patients present with ALI despite normal baseline imaging. This paradox can obscure timely diagnosis and delay intervention. Understanding the underpinning mechanisms, diagnostic nuances, and current best practices is essential for optimizing outcomes in these patients. This review synthesizes current evidence and guideline-driven approaches for clinicians encountering ALI with normal initial imaging findings.

Epidemiology / Disease Burden

ALI is a significant contributor to morbidity and mortality worldwide. Epidemiological data suggest an incidence of 10–20 cases per 100,000 population annually in developed nations, with higher prevalence in regions with endemic viral hepatitis or widespread use of hepatotoxic drugs. The precise burden of ALI presenting with normal imaging is less well-characterized, as these cases are often underrecognized. Studies indicate that up to 20% of ALI presentations, particularly in early stages or with predominant hepatocellular injury, may not show radiographic abnormalities. This subset poses distinct diagnostic and management challenges, underscoring the need for heightened clinical vigilance.

Pathophysiology

The pathogenesis of ALI with unremarkable imaging is multifactorial. Hepatocellular injury commonly results from direct cellular toxicity (e.g., medications, toxins), ischemic insults, viral infections, or autoimmune mechanisms. In early or mild ALI, structural changes may not be substantial enough to be detected by conventional imaging. Cellular swelling, microvesicular steatosis, or early necrosis may precede gross architectural distortion. Additionally, hepatic reserve and regenerative capacity can mask early parenchymal changes, explaining the discordance between biochemical derangement and imaging findings.

Risk Factors

Risk factors for ALI with normal imaging parallel those of ALI generally but are particularly relevant in certain populations. These include recent initiation of potentially hepatotoxic medications (e.g., acetaminophen, antibiotics, antiepileptics), acute viral hepatitis, ischemic episodes (e.g., hypotension, shock), autoimmune hepatitis, and metabolic insults. Genetic predispositions, such as polymorphisms in drug-metabolizing enzymes, and comorbidities like obesity or alcohol misuse, may exacerbate susceptibility. The absence of imaging findings should not lower clinical suspicion in high-risk individuals.

Clinical Features

Patients may present with non-specific symptoms such as malaise, anorexia, nausea, right upper quadrant discomfort, or jaundice. Physical examination may uncover hepatomegaly, tenderness, or stigmata of chronic liver disease in some cases. However, early ALI can be clinically silent or manifest only as incidental laboratory abnormalities. The absence of radiological signs may lead to underestimation of severity, reinforcing the importance of thorough history, risk assessment, and laboratory evaluation.

Diagnosis

Diagnosis of ALI relies primarily on biochemical evidence, specifically marked elevation in aminotransferases (ALT, AST) often out of proportion to alkaline phosphatase or bilirubin early in the course. Coagulation profile (INR), serum bilirubin, and albumin levels help assess hepatic synthetic function. Exclusion of chronic liver disease and careful medication, toxin, and infectious workup are crucial. Imaging ultrasound, CT, or MRI serves to rule out obstructive, vascular, or space-occupying lesions. A normal initial imaging study does not exclude significant hepatic injury. Liver biopsy may be warranted in select cases to clarify etiology, particularly in suspected autoimmune or infiltrative diseases.

Treatment & Management

Management is etiology-specific and supportive. Immediate discontinuation of offending agents, hemodynamic stabilization, and correction of precipitating factors are priorities. N-acetylcysteine is indicated for acetaminophen toxicity and may benefit non-acetaminophen ALI. Antiviral therapy is considered for viral hepatitis, while immunosuppression is reserved for autoimmune hepatitis. Monitoring for progression to acute liver failure, characterized by encephalopathy and coagulopathy, is essential. Serial laboratory assessment, vigilant clinical monitoring, and multidisciplinary involvement are recommended.

Recent Advances / Emerging Therapies

Recent advances include novel biomarkers for early detection, such as glutamate dehydrogenase and microRNA panels, which may identify ALI prior to imaging changes. Machine learning models integrating clinical and laboratory data are under investigation to improve risk stratification. Therapeutic plasma exchange and extracorporeal liver support devices show promise in severe cases. Research into hepatoprotective agents, such as farnesoid X receptor agonists and mesenchymal stem cell therapy, is ongoing, offering potential for future targeted interventions.

Guideline Recommendations

Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) emphasize a structured approach: prompt recognition, thorough etiological investigation, and early specialist referral. They advocate for not excluding ALI on the basis of normal imaging alone, highlighting the primacy of laboratory and clinical findings. Timely intervention, monitoring for complications, and consideration of transplantation in fulminant cases are key recommendations.

Conclusion

ALI with normal initial imaging represents a diagnostic and clinical challenge. Awareness of this presentation, integration of clinical and laboratory data, and adherence to evidence-based management pathways are essential for optimizing patient outcomes. Emerging biomarkers and therapies hold promise for earlier diagnosis and improved prognostication. Clinicians must maintain a high index of suspicion and act decisively even in the absence of radiological evidence of liver injury.